*Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal.
†Department of Microbiology, Immunology and Molecular Genetics, University of California, 615 Charles East Young Drive East, Los Angeles, CA 90024, U.S.A.
Biochem J. 2014 Apr 1;459(1):161-70. doi: 10.1042/BJ20131058.
It was reported recently that a new aryl methyldiene rhodanine derivative, LJ001, and oxazolidine-2,4-dithione, JL103, act on the viral membrane, inhibiting its fusion with a target cell membrane. The aim of the present study was to investigate the interactions of these two active compounds and an inactive analogue used as a negative control, LJ025, with biological membrane models, in order to clarify the mechanism of action at the molecular level of these new broad-spectrum enveloped virus entry inhibitors. Fluorescence spectroscopy was used to quantify the partition and determine the location of the molecules on membranes. The ability of the compounds to produce reactive oxygen molecules in the membrane was tested using 9,10-dimethylanthracene, which reacts selectively with singlet oxygen (1O2). Changes in the lipid packing and fluidity of membranes were assessed by fluorescence anisotropy and generalized polarization measurements. Finally, the ability to inhibit membrane fusion was evaluated using FRET. Our results indicate that 1O2 production by LJ001 and JL103 is able to induce several changes on membrane properties, specially related to a decrease in its fluidity, concomitant with an increase in the order of the polar headgroup region, resulting in an inhibition of the membrane fusion necessary for cell infection.
最近有报道称,一种新型芳基甲叉基罗丹宁衍生物 LJ001 和恶唑烷-2,4-二硫酮 JL103 通过作用于病毒膜来抑制其与靶细胞膜融合。本研究旨在探讨这两种活性化合物以及用作阴性对照的无活性类似物 LJ025 与生物膜模型的相互作用,以阐明这些新型广谱包膜病毒进入抑制剂在分子水平上的作用机制。荧光光谱法用于定量分配并确定分子在膜上的位置。使用 9,10-二甲基蒽来测试化合物在膜中产生活性氧分子的能力,9,10-二甲基蒽选择性地与单线态氧(1O2)反应。通过荧光各向异性和广义极化测量评估膜的脂质堆积和流动性变化。最后,通过 FRET 评估抑制膜融合的能力。我们的结果表明,LJ001 和 JL103 产生的 1O2 能够诱导膜性质发生多种变化,特别是与流动性降低相关,同时极性头部区域的有序性增加,导致抑制细胞感染所需的膜融合。